Who We Are

pride2014-3

HIV Prevention Program staff taking part in Pittsburgh Pride Festival 2014

CAB group 6.4.14 Mtg

Members of our Community Advisory Board (CAB)

actg
Our Mission

The mission of the AIDS Clinical Trials Group (ACTG) Network is:

To develop and conduct scientifically rigorous translational research and clinical trials to (1) investigate the viral and immune pathogenesis of HIV-1 infection and its complications; (2) evaluate novel drugs and strategies for treating HIV-1 infection; (3) evaluate interventions and strategies to treat and prevent HIV-related co-infections and co-morbidity, and; (4) publish and disseminate results to improve care, and reduce or eliminate morbidity and mortality associated with HIV-1 infection and its complications.

The mission of the ACTG’s web properties is to support the ACTG Network through the effective use of internet and social media technology to provide timely and valuable information to our global users, including: HIV/AIDS research networks, clinical research sites, pharmaceutical companies, laboratories, data management center, investigators, community members, and other organizations. The ACTG’s web properties are comprised of the public and member websites and a file-sharing portal website.

Specific goals for the ACTG’s web properties include:
•Enhancing the ACTG Network’s presence on the internet by broadening information on ACTG’s studies, sites, committees, communities, laboratories, publications, and other entities;
•Providing news and information relating to the ACTG network’s events and activities;
•Developing automated processes for protocol development and management performance evaluation, as well as abstract, manuscript, and publication submissions;
•Enhancing dashboard and reporting capabilities;
•Allowing online application submissions;
•Facilitating communication and collaboration among ACTG users worldwide.

mtn

MTN: Microbicide Trials Network

The Microbicide Trials Network (MTN) is an HIV/AIDS clinical trials network established in 2006 by the National Institute of Allergy and Infectious Diseases (NIAID), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health, all of the U.S. National Institutes of Health (NIH). The MTN brings together international investigators and community and industry partners whose work is focused on the development and rigorous evaluation of promising microbicides – products applied inside the vagina or rectum that are intended to prevent the sexual transmission of HIV. Whether a small Phase I study testing a product’s safety and acceptability or a large-scale Phase III trial evaluating its effectiveness, every MTN trial is designed to collect the kind of data regulatory agencies require for determining whether to approve a product for widespread use. Because the effectiveness of a product is also dependent on its use, behavioral and social science is embedded within each study to gain understanding of the needs and desires of different high-risk groups. MTN’s research agenda includes populations considered among those at highest risk, including women in Sub-Saharan Africa, adolescents, pregnant and breastfeeding women, transgender women and men who have sex with men (MSM). More than 25 clinical research sites on four continents partner with the MTN in the conduct of its clinical trials.